AI Terminal
Fresenius SE & Co. KGaA
Earnings Release • Feb 1, 2021
166_rns_2021-02-01_4010207d-b731-49d3-8a90-c4dc24363d96.html
Earnings Release
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 1 February 2021 22:49
Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21
Fresenius SE & Co. KGaA / Key word(s): Forecast
Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21
01-Feb-2021 / 22:49 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Fresenius SE & Co. KGaA: Excess mortality of dialysis patients impacts Group net income in FY/21
Current Group expectations for FY/21
Based on the current status of the Group’s financial planning process and assuming that the current burdens and constraints caused by the COVID-19 pandemic only begin to recede in the second half of the year, Fresenius targets healthy sales growth 1 and at least broadly stable net income 2 year over year in FY/21. The FY/21 earnings are, hence, expected to be very meaningfully impacted by COVID-19 effects. In particular, as reported today by Fresenius Medical Care, the significant acceleration of mortality among dialysis patients due to COVID-19 is expected to have a material impact on Fresenius Medical Care’s results and hence on Fresenius Group’s net income 2 growth.
Group medium-term targets
The current information and assumptions do not trigger a revision of Fresenius’ medium-term growth targets, which were set before the COVID-19 pandemic emerged.
Fresenius will announce more detailed FY/21 financial guidance with the release of its FY/20 results on February 23, 2021.
1 in constant currency
2 Net income attributable to shareholders of Fresenius SE & Co. KGaA; in constant currency; before any special items and any one-time expenses related to likely efficiency and cost saving programs
For additional information on the performance indicators used please refer to our website at https://www.fresenius.com/alternative-performance-measures .
Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
The Management Board
Bad Homburg v.d.H., February 1, 2021
—————————————-
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
—————————————-
End of Note
01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Fresenius SE & Co. KGaA |
| Else-Kröner-Straße 1 | |
| 61352 Bad Homburg v.d.H. | |
| Germany | |
| Phone: | +49 (0)6172 608-2485 |
| Fax: | +49 (0)6172 608-2488 |
| E-mail: | [email protected] |
| Internet: | www.fresenius.com |
| ISIN: | DE0005785604 |
| WKN: | 578560 |
| Indices: | DAX |
| Listed: | Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange |
| EQS News ID: | 1164992 |
| End of Announcement | DGAP News Service |